Meeting
2021 Gastrointestinal Cancers Symposium
ARC-9: Phase Ib/II study to evaluate etrumadenant (AB928)-based treatment combinations in patients with metastatic colorectal cancer (mCRC).
Authors
Michael Cecchini
Yale University, New Haven, CT
Michael Cecchini , Kartik Krishnan , Nick Giafis , Jennifer Scott , Cheng Seok Quah , Johanna C. Bendell
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session: Colorectal Cancer
Track
Colorectal Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr TPS150)
DOI
10.1200/JCO.2021.39.3_suppl.TPS150
Abstract #
TPS150
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Efficacy and safety of 5-fluorouracil (5-FU) / levofolinate / irinotecan (FOLFIRI) for previously treated advanced pancreatic cancer (APC).
First Author: Hiromichi Shirasu
Poster
2021 Gastrointestinal Cancers Symposium
MOUNTAINEER: open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress).
First Author: John H. Strickler
Poster
2017 Gastrointestinal Cancers Symposium
A randomized phase II study to investigate the deepness of response (DpR) of FOLFOXIRI plus cetuximab (Erbitux) versus FOLFOXIRI plus bevacizumab as the first-line therapy in metastatic colorectal cancer (mCRC) patients with RAS wild-type tumors: DEEPER.
First Author: Akihito Tsuji
Poster
2016 Gastrointestinal Cancers Symposium
Bevacizumab effectiveness and primary tumor location in metastatic colorectal cancer patients.
First Author: Wen-zhuo He